Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rinvoq. Always confirm against the full prescribing information.
100 interactions
Abacavir
The risk or severity of liver damage can be increased when Abacavir is combined with Upadacitinib.
Level 2 evidence
Abemaciclib
The risk or severity of liver damage can be increased when Abemaciclib is combined with Upadacitinib.
Level 2 evidence
Abiraterone
The risk or severity of liver damage can be increased when Abiraterone is combined with Upadacitinib.
Level 2 evidence
Acalabrutinib
The risk or severity of liver damage can be increased when Acalabrutinib is combined with Upadacitinib.
Level 2 evidence
Acamprosate
The risk or severity of liver damage can be increased when Acamprosate is combined with Upadacitinib.
Level 2 evidence
Acarbose
The risk or severity of liver damage can be increased when Acarbose is combined with Upadacitinib.
Level 2 evidence
Acebutolol
The risk or severity of liver damage can be increased when Acebutolol is combined with Upadacitinib.
Level 2 evidence
Aceclofenac
The risk or severity of liver damage can be increased when Aceclofenac is combined with Upadacitinib.
Level 2 evidence
Acetaminophen
The risk or severity of liver damage can be increased when Acetaminophen is combined with Upadacitinib.
Level 2 evidence
Acetazolamide
The risk or severity of liver damage can be increased when Acetazolamide is combined with Upadacitinib.
Level 2 evidence
Acetohydroxamic acid
The risk or severity of liver damage can be increased when Acetohydroxamic acid is combined with Upadacitinib.
Level 2 evidence
Acetylsalicylic acid
The risk or severity of liver damage can be increased when Acetylsalicylic acid is combined with Upadacitinib.
Level 2 evidence
Enter your NPI to unlock 23 major interactions for Rinvoq
Rinvoq (Upadacitinib) has 986 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rinvoq (Upadacitinib) has 206 major, 743 moderate, and 37 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rinvoq. Always confirm against the full prescribing information.